Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A treatment offer develops through customer stories, product education, the care process and a clear purchase entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The handwriting and the red stamp make a funny, unexpected scene in a category that's usually earnest, which earns a second look. More importantly, it speaks to a specific person: someone who used to dismiss GLP-1s and has changed their mind, the same skeptic Brello's creator video addresses. The ad also gives that person a graceful way back in, since the brand accepts the apology instead of saying I told you so.
The ad teases the perks instead of naming them, with a line asking viewers to wait until they see all the perks that are included. That pushes the most persuasive information behind the click, so a viewer still on the fence has nothing to weigh except the per-day price. The per-day figure also doesn't appear on the landing page, which leads with $166 a month and $499. Name two perks in the ad (provider messaging and the community are in the caption already) and carry the daily price onto the page.
The personal tone and humor stop the scroll in a serious category.
It answers the skeptic warmly and makes the brand the one forgiving, not judging.
A daily price keeps the cost feeling small right after the emotional beat.
It tries to create curiosity, though it holds back the details that would persuade.
Tirzepatide at about $5.94 a day (if approved), with fine print restating it as $166 a month on a three-month minimum that renews for $499 every 11 weeks.
The ad sends people to tirzepatidewoo.brellohealth.com, a dedicated Tirzepatide offer page rather than the homepage or a quiz, and it's one of 18 Brello ads in the library that point there. The perks the ad teases are all on the page: the plan and purchase entry under What makes Brello different lists classes, community, provider review, the delivery kit, the app and the pharmacy, so the curiosity pays off if people scroll. The price changes shape on arrival, though, from $5.94 a day to $166 a month and a $499 plan. The skeptic angle doesn't continue either, and a short line in the hero for people who are new to GLP-1s or changed their mind would keep the story going.
Brello's dedicated Tirzepatide offer page opens on a $166 a month special with the three-month plan box, then moves through reviews, treatment education, a four-step care path, inclusions and FAQs. It's where 18 Brello ads in the library land, all static image ads, built on emotional moments, native-style text posts and offer or inclusion lists.
A price lock banner, the vial with a $166 badge, and a plan box with the $499 three-month plan, Trustpilot rating, transfer note and intake explanation, answering what it costs and what happens when you pay.
Trusted by 80,000+ members with a Trustpilot rating and review cards about community, customer service and members' own results, answering whether people like you have done this.
A deeper look inside Tirzepatide, with a short explanation, a list of what studies examine, footnoted sources and a results-may-vary note, answering what the medication is.
A straightforward path to care in four photo steps (select your plan, provider review, ships to your door, ongoing support), answering how the process works.
What makes Brello different, with six inclusions beside a photo and a Take the First Step button, answering what you get beyond the medication.
Six questions on approval, refunds, timelines and replacements, then the study references, disclaimers and plan terms, answering the last practical doubts.
Read the full breakdown of this page
One of 22 Brello Health ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.